Drug updated on 11/4/2024
| Dosage Form | Injection (subcutaneous; 600 mcg/2.4 mL [250 mcg/mL]) |
| Drug Class | Parathyroid hormone analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
- Indicated for the increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
- Indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.
Latest News
Summary
- This summary is based on the review of 23 systematic review(s)/meta-analysis(es). [1-23]
- Teriparatide significantly increased bone mineral density (BMD) at the femoral neck, total hip, and lumbar spine compared to bisphosphonates in osteoporosis patients without prior bisphosphonate treatment, with similar BMD improvements noted in pregnancy and lactation-associated osteoporosis (PLO) patients over calcium/vitamin D and bisphosphonate treatments.
- Teriparatide reduced fracture risk more effectively than bisphosphonates (RR (relative risk) = 0.61, 95% CI (confidence interval) [0.51, 0.74], P < 0.001) and showed significant reductions in vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) (RR = 0.11, 95% CI [0.03-0.47]) as well as in new osteoporotic vertebral fractures compared to bisphosphonates like alendronate and risedronate.
- Combined with percutaneous vertebroplasty (PVP) surgery, teriparatide resulted in significantly lower VAS pain scores compared to PVP alone, indicating enhanced pain relief in fracture management (MD = -4.99, 95% CI = [-7.45, -2.52]).
- In cases of atypical femoral fractures and nonunion, teriparatide improved time to bone union and facilitated early bone healing compared to controls, supporting its role in fracture healing.
- Teriparatide showed no significant increase in general adverse events compared to bisphosphonates (RR = 0.92, 95% CI [0.79, 1.08], P = 0.32) and similarly did not lead to increased adverse events when compared to denosumab.
- Clinical trials and post-marketing surveillance indicate no elevated risk of osteosarcoma with teriparatide use, addressing a specific safety concern associated with this therapy.
- Hypercalcemia was reported at a lower incidence in patients treated with abaloparatide compared to those receiving teriparatide, while romosozumab was associated with fewer injection-site reactions than teriparatide.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Forteo (teriparatide) Prescribing Information. | 2024 | Eli Lilly and Company, Indianapolis, IN |